A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases

Trial Profile

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Focal segmental glomerulosclerosis; IgA nephropathy; Polycystic kidney disease; Renal failure
  • Focus Therapeutic Use
  • Acronyms PHOENIX
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 23 Jul 2018 Results presented in the Reata Pharmaceuticals media release.
    • 25 May 2018 Results presented in the Reata Pharmaceuticals media release.
    • 25 May 2018 According to a Reata Pharmaceuticals media release, positive interim data from the autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy cohorts of this study are being presented at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top